Lilly cuts self-pay Zepbound prices as federal TrumpRx site lists $299 starting tier

Eli Lilly agreed to lower the cash prices of its self-pay Zepbound tiers, and the federal drug-pricing site TrumpRx.gov now lists Zepbound starting at $299 a month ^[1]. Zepbound is tirzepatide, Lilly's brand-name injectable approved for weight loss.

TrumpRx.gov is a directory, not a pharmacy. For Zepbound, the listing sends visitors to LillyDirect, Lilly's direct-to-patient platform, where the order is actually placed and the medication is filled ^[1]. Going through TrumpRx reaches the same product at the same price as going straight to LillyDirect, according to the pricing page ^[1]. The federal site launched February 5, 2026, with medicines from five companies, including Lilly and Novo Nordisk, and the $299 starting figure was shown on TrumpRx.gov itself and in Eli Lilly's December 2025 pricing announcement ^[1].

The price depends on the dose. Under self-pay terms revised in March 2026, the 2.5 mg starting dose is $299 a month, 5 mg is $399, and 7.5 mg through 15 mg are $449, against an original list price of about $1,087 ^[1]. The higher-dose price carries a condition: it holds only if the refill happens within 45 days. A late fill costs $499 at 7.5 mg and $699 at 10 mg, 12.5 mg and 15 mg, plus taxes and fees ^[1]. A one-month supply is 28 days, delivered as four vials or one KwikPen, and the terms apply to both forms ^[1].

Because 2.5 mg is a starter dose rather than a maintenance dose under the FDA label, the $299 headline often does not match what people pay over time, the page states ^[1]. Its estimate for someone who moves from 2.5 mg to 5 mg and then to 7.5 mg or higher while refilling on time is about $430 a month, or roughly $5,188 over a year. Staying at 5 mg with on-time refills comes to about $4,688 a year ^[1]. An older blended figure of about $350 that still appears in some cost articles is out of date, according to the page ^[1].

Compounded tirzepatide is a separate, non-FDA-approved category that TrumpRx does not offer ^[1]. Zepbound itself remains prescription-only, and LillyDirect expects a valid on-label prescription ^[1].

Why it matters for patients

The lower tiers matter most to people who pay cash because insurance does not cover Zepbound or covers it poorly. The sticker price is not the whole cost: the dose and refill timing move the monthly figure, and a missed 45-day window can add $50 to $250 to a single fill ^[1]. The page reports that insurance or Medicare can be cheaper than any cash price, and that a savings card can bring commercially insured patients to as little as $25 a month, while government insurance cannot use that card ^[1]. For Medicare Part D members, a separate program described below is scheduled to offer the KwikPen at $50 a month for those who qualify ^[1].

Patients weighing compounded tirzepatide against brand-name Zepbound are looking at two different categories: one FDA-approved and listed on the federal site, the other not FDA-approved and not offered through TrumpRx ^[1]. Neither route removes the need for a prescription and a clinician's evaluation; for on-label use, the page cites a BMI of 30 or higher, or 27 or higher with a weight-related condition ^[1].

What happens next

A Medicare GLP-1 Bridge program is scheduled to begin July 1, 2026, covering the KwikPen at $50 per 30-day supply for eligible Part D members, with prior authorization required. It would not cover the vial or the single-dose pen ^[1]. The pricing page notes that prices and program rules change quickly, and that it re-checks its linked sources monthly ^[1].

Lilly added Walmart pharmacy pickup as a delivery option in late 2025 ^[1]. No further changes to the self-pay tiers have been announced beyond the March 2026 terms described here ^[1].